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Immunological mechanisms involving both humoral and cellular immunity 
may be  important  in  host defense against viral-induced neoplastic  diseases. 
Humoral antibodies can neutralize many viruses (1), and some antibodies can 
kill virus-infected or transformed cells in the presence of complement, normal 
lymphoid cells,  or  peritoneal  exudate  cells  (2-5).  In  some systems cytotoxic 
antibodies correlate with tumor rejection (6-8) and passively transferred anti- 
bodies can protect against subsequent tumor cell challenge (9,  10). However, 
humoral factors, presumably specific antibodies or antigen-antibody complexes, 
can also exert an inhibitory effect on the host cell-mediated immune response to 
tumor cells in vitro (11, 12) and can enhance tumor progression in vivo (13, 14). 
Spontaneous recovery from Friend virus (FV) ~ mouse leukemia is often seen 
in certain mouse strains (15). The host immune responses to both the virus and 
the neoplastic cells probably play a critical role in this recovery. Furthermore, 
recovery has been shown to be markedly influenced by a  single gene (Rfv-1) 
located in the D-region of the major histocompatibility complex (H-2) (16). Since 
this gene primarily affects recovery from leukemia rather than susceptibility to 
virus infection or cell transformation, it seems likely that some aspects of the 
host specific immune response might be influenced by this gene. The present 
experiments were undertaken to investigate the roles of host humoral antiviral 
and antileukemia cell immune responses in congenic mouse strains differing 
only at the H-2 complex. The data suggest that neutralizing anti-FV antibody 
may play a  key role in control of viral infection. However, in spite of the fact 
that neutralizing or cytotoxic antibodies can inhibit focal leukemia cell growth 
in vivo, these antibodies are not sufficient to induce recovery from leukemia. In 
addition, other non-H-2-1inked genes were shown to affect host control of viral 
infection and Rfv-l-mediated recovery from leukemia. 
Materials and Methods 
Buffer.  pH  7.3, phosphate-buffered  balanced salt  solution (PBBS)  contained NaC1, 7,200 
mg/liter; KC1, 320 mg/liter; Na~HPO4, 1,150 rag/liter; KH2PO4, 200 mg/liter; CaC12, 140 rag/liter; 
i Abbreviations  used in this paper: B/r-L, BALB Tennant leukemia virus; FFU, focus-forming 
units; FV, Friend leukemia virus; PBBS, phosphate-buffered balanced salt solution; RML, Rocky 
Mountain Laboratory. 
THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE"  VOLUME 143, 1976  73 74  HUMORAL  IMMUNITY  AND  RECOVERY  FROM  LEUKEMIA 
MgCI2"6H~O,  200  mg/liter;  MgSO4'7H20,  200  mg/liter;  glucose,  1,000  mg/liter; phenol red,  10 
rag/liter.  PBBS  with 5%  fetal calf serum was used as  diluent in neutralization and cytotoxic 
antibody tests. 
Animals.  Mouse strains used  were previously described (16). In  addition,  F~  hybrid mice 
(B10.A  ×  A/WySn)F~ and (B10.D2  ×  BALB/c)F~  and backcross mice (C57BL/10  ×  BALB.B)F1  x 
BALB.B were bred at the Rocky Mountain Laboratory (RML).  For neutralization tests,  RML 
random bred white mice were used. 
Virus.  The B-tropic strain of Friend virus was grown, stored, inoculated, and assayed for 
focus-forming units (FFU) as before (16). FV stocks were also made in (C57BL/10  x  A.BY)F~  and 
(B10.A × A/WySn)F~ mice from spleen homogenates 8 days after i.v. inoculation of 15,000 FFU of 
virus. NB-tropic Friend virus was used in neutralization tests only. This strain was obtained from 
Dr. Frank Lilly, Department of Genetics, Albert Einstein College of Medicine, Bronx, N. Y.  and 
was propagated in BALB/c mice. 
Recovery  Experiments.  ll-16-wk-old  mice were  injected  i.v.  with  FV  and  were  palpated 
weekly for splenomegaly while under ether anasthesia, as previously described (16). 
Virus Growth.  Kinetics of FV growth in the spleens of infected mice was followed by  i.v. 
inoculation of dilutions of freshly prepared 10% spleen homogenates into (BALB/c × A/J)F~  mice. 
The spleens of the recipient mice fixed in Bouin's solution 9 days later, and foci were counted (17). 
Results were expressed as FFU/donor spleen. 
Viremia.  Mice  were tail  bled  into heparinized capillary tubes.  Plasma  was  separated by 
centrifugation. Presence of viremia was determined by i.v. inoculation of 4 ~l fresh plasma in 0.5 
ml PBBS into (BALB/c × A/J)F~  mice. These mice were palpated weekly for 8 wk for splenomeg- 
aly. Those without splenomegaly were considered to have received nonviremic plasma. 
Virus Neutralization.  10 ~l of serial threefold dilutions of plasma or serum was mixed with 50 
~l diluent containing 200 FFU NB-tropic FV. The mixtures were incubated 3 h  at 37°C,  diluted 
with 1.5 ml diluent at 0°C, and 0.5 ml was injected i.v. into RML mice. Mice were killed 9 days 
later, and spleens were fixed and foci counted as usual.  The titer was expressed as the highest 
dilution giving ->50% reduction in the number of foci observed. 
Antibody Plus Complement  Mediated  Cytotoxicity.  Targets were either spleen cells from mice 
that had received 15,000 FFU FV i.v.  9 days earlier or BC-3A lymphoma cells derived from a 
primary lymphoma occurring 2 mo after inoculation of newborn BALB/c mice with Bfr-L (Ten- 
nant) leukemia virus (18). BC-3A cells were propagated in vivo as an ascites tumor line or in vitro 
in stationary suspension cultures in RPMI 1640 with 10% fetal calf serum and 10 ~M 2-mercapto- 
ethanol. These cells have the Friend-Moloney-Rauscher antigen (2) on their surface, as demon- 
strated by cross-absorption experiments, and all sera tested simultaneously against both BC-3A 
and 9-day FV spleen targets gave identical cytotoxic antibody titers. 
10-50  ×  106 target cells were labeled with 150 ~Ci 5~Cr (Na~CrO4) in 0.6 ml PBBS at 37°C for 30 
rain. Cells were washed three times with diluent and resuspended at a  concentration of 4  ×  106 
cells/ml for use. 25 t~l serial twofold dilutions of sera or plasmas to be tested were made in Linbro 
round bottomed well microtiter trays (Linbro Chemical Co., New Haven, Conn.) 25/~l containing 1 
×  105 labeled targets was added, and the mixture incubated 30 rain at 37°C. Due to the frequent 
occurrence of anticomplementary activity in the sera, targets were washed twice with diluent 
before addition of complement (C'). After the second wash, 25 ~1 diluent was added to each well, 
and 50  ~1 of a  one:four or one:eight dilution of absorbed rabbit serum was added as C'  source. 
The mixture was incubated 45 min at 37°C and the trays centrifuged 1,000 rpm for 5 min. 50/~l of 
supernate was removed from each well and counted in an automatic gamma counter. Control wells 
contained targets plus C' alone and targets plus diluent alone. Percent lysis was calculated as: 
cpm with antibody -  cpm with diluent only  ×  100 
total releasable cpm targets -  cpm with diluent only 
Rabbit serum for C'  was absorbed at 0°C  for 30  rain in 0.01  M  EDTA  with washed ascites 
leukemia cells (BC-3A or LSTRA) in a  ratio of 1 ml packed cells per 5 ml rabbit serum.  After 
absorption the cells were sedimented, serum removed, recalcified with CaCI2, and frozen at -70°C 
in small aliquots. After absorption percent lysis of target cells by C' alone varied from 2-12%. The 
titer of cytotoxic antibodies in sera was expressed as the highest dilution giving > 15% lysis above 
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TABLE  I 
Effect of Passive Antibody Transfer  on FV Spleen Foci 
Treatment*  Day  Foci  P$ 
Avg +-- SE 
None  --  13.6 -+ 2.1  -- 
NMS§  1  12.0 -+ 3.7  <0.05  Anti-FV serum  1  2.0 -+ 1.1 
NMS  3  27.5  -+ 6.0  <0.02  Anti-FV serum  3  5.5 -+ 3.2 
NMS  6  21.7  -+ 6.1  >0.1  Anti-FV serum  6  21.7 -+ 2.4 
* (B10.A x A.BY)F~ mice received FV (20 FFU, i.v.) on day 0 and 0.2 ml 
serum i.p. on the subsequent day as indicated. 
$ P  values comparing treatment with anti-FV serum and normal mouse 
serum given on the same day. 
§ Normal mouse serum. 
Passive Antibody Transfer.  Hyperimmune anti-FV serum was produced in (B10.A  x A.BY)F~ 
mice by i.v. inoculation of 300 FFU of FV. 30 days later 15,000 FFU was inoculated i.v., and this 
dose was repeated at 14-day intervals. Mice were bled 7 days after the third, fourth, and sixth 
inoculations. Pooled sera from each strain had an anti-FMR cytotoxic antibody titer of 128-256 and 
a FV neutralizing titer of 258-900. 
Passive antibody transfer experiments were done in (B10.A  x  A.BY)F~ mice given 25 FFU of 
FV i.v. Groups of 4-5 mice were then given 0.3 ml syngeneic anti-FV serum or normal syngeneic 
serum i.p. 1, 3, or 6 days later. One group received no serum. All mice were sacrificed on the 9th 
day after virus and spleen loci were counted. 
Results 
Effect of Passive Antibody  Transfer on Spleen Foci.  To  assess the  in  vivo 
effects of humoral  antibodies on FV infection and development  of leukemia  in 
mice with  a  low incidence  of spontaneous  recovery,  passive antibody  transfer 
experiments  were  carried  out.  Anti-FV  serum,  containing  FV  neutralizing 
antibodies as well as cytotoxic antibodies for FV-induced cell surface antigens, 
or normal serum was given to (B10.A  x  A.BY)F~ mice at 1, 3, or 6 days after FV 
inoculation,  and mice were examined  for spleen loci on the 9th day. The results 
(Table I) indicate that  anti-FV  serum  given 1 or 3  days after virus reduced the 
number  of virus-induced  spleen foci  seen.  Antiserum  given on  day 6  was  not 
effective.  Since cell transformation  in the spleen can occur as early as several 
hours  after  FV  inoculation  (19),  antibody  transferred  1  or  3  days  after  virus 
probably does not act solely by interfering with primary  infection and transfor- 
mation.  It is likely that, analogous to the situation in vitro, antibodies to virus- 
induced  cell surface  antigens  together  with  complement  or  normal  lymphoid 
cells  can  mediate  lysis or  inhibit  growth  of virus-transformed  cells and  thus 
could theoretically form an effective host defense mechanism  against  leukemia 
cells. 
Friend Virus Growth and Neutralizing Antibodies.  To investigate  possible 
correlations between humoral  antibody response and recovery from FV-induced 
leukemia,  a  kinetic  experiment  was  set  up  to  examine  splenomegaly,  virus 
growth, and appearance  of antibody in two congenic mouse strains differing only 76  HUMORAL  IMMUNITY  AND  RECOVERY  FROM  LEUKEMIA 
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DAYS AFTER FV INOCULATION 
FIG.  1.  Comparison of virus growth, spleen weight, incidence ofviremia, and neutralizing 
antibody titer after the inoculation of congenic F, mice with 15,000 FFU FV ([C57BL/10  × 
A.BY]F~  stock).  Each point represents the geometric mean of the values obtained from 3-8 
mice. 
for  genes  within  the  H-2  complex.  Female  (B10.A  ×  A.BY)F,  (1"1-2  "lb)  and 
C57BL/10  ×  A.BY)F1(H-2 bib) mice were inoculated  i.v.  with 15,000  FFU  of B- 
tropic FV ([C57BL/10  ×  A.BY]F1  stock), and on subsequent days groups of 3-8 
mice  were  examined  for  viremia,  FV  neutralizing  and  cytotoxic  antibodies, 
spleen weight, and total amount of FV per spleen. Results are shown in Fig.  1. 
In  agreement  with  previous  data  concerning  the  effect  of the Rfv-1  gene  on 
recovery from FV leukemia (16), both strains of mice developed splenomegaly by 
the  9th  day.  However,  during the  following weeks the  spleens  of H-2 bib  mice 
returned to near normal  size  while those of the 1"1-2  ~lb mice remained  grossly 
enlarged. In spite of the strain differences in recovery from splenomegaly, there 
appeared to be very little difference in the kinetics of viral growth and elimina- BRUCE  CHESEBRO  AND  KATHY  WEHRLY  77 
tion.  Both strains had peak spleen FV titers and 100% incidence of viremia on 
day  9,  and  both  strains  showed  a  progressive  drop  in  spleen  FV  titer  and 
incidence of viremia over the following 1-3 wk. By day 22 no mice had viremia, 
and by day 34 no spleen FV was detectable. Coincident with the fall in spleen 
and plasma virus levels all mice developed significant titers of FV neutralizing 
antibody  (Fig.  1)  and  cytotoxic antibody (data  not  shown).  There  were some 
differences between the strains. H-2 ajb mice had slightly higher spleen FV levels 
on days 3 and 9 and eliminated the virus at a  slower rate than H-2 bib mice. The 
time of reduction of virus levels varied from day 13 to 32 among individual H-2 a~b 
mice,  however,  there  was always a  direct correlation  in  individuals  between 
presence  of neutralizing  and  cytotoxic antibody  and  reduction  in  spleen  FV 
level. On days 9, 13, and 17 several individuals had both viremia and neutraliz- 
ing antibody at the same time. This could probably be explained by the existence 
of some infectious virus-antibody immune complexes in these plasmas. 
The  excellent correlation  between humoral  antiviral  immune  response  and 
control  of virus  infection  indicates  that  neutralizing  antibodies  could play a 
crucial role in restricting FV growth. However, there was a striking contrast in 
H-2 alb  mice  between control  of infection  and  lack  of control  of the  leukemic 
process in the presence of good neutralizing and cytotoxic antibody responses. 
Cytotoxic  Antibodies.  The role of cytotoxic antibodies in recovery from FV 
leukemia was investigated by examining hybrid mice of the Rfv-1  high (b/b) and 
low  (d/b  or a/b)  recovery  genotypes  30-35  days  after  FV  inoculation.  BALB 
hybrids, (C57BL/10 ×  BALB/c)F1 (H-2 dlb) and (C57BL/10 ×  BALB.B)F1 (H-2blb), 
were given 150 FFU of FV raised in BALB.B mice. A.BY hybrids, (C57BL/10 × 
A.BY)F1 (H-2 bib) and (B10.A  ×  A.BY)F1 (H-2~lb),  were given 15,000  FFU of FV 
raised in (C57BL/10 × A.BY)F~ mice. s The results are shown in Fig. 2. All BALB 
hybrids developed cytotoxic antibody titers  of eight  or greater.  Although  the 
incidence  of  recovery  from  splenomegaly  was  markedly  different  between 
strains (H-2 dlb, 1/9; H-2 bib, 9/11), there was no difference in the range of cytotoxic 
antibody titers observed, which suggests that cytotoxic antibodies are not the 
critical  factor in  determining  the  different recovery incidences  seen  in these 
strains.  Examination of A.BY hybrids revealed similar results with significant 
cytotoxic  antibody  titers  present  in  both  strains  regardless  of the  status  of 
recovery from splenomegaly (H-2 bib, 30/30; H-2 ~jb, 11/33). Neutralizing antibody 
titers in all the mice were uniformly high (72-258). There were 5 H-2 ~lb individ- 
uals with  splenomegaly that  had  no detectable cytotoxic antibody titer  at 30 
days, however, on subsequent bleeding 4 wk later they all had titers of eight or 
greater and still had gross splenomegaly. 
Because of the unexpected occurrence of cytotoxic antibodies in splenomegalic 
mice 30 days or more after virus inoculation, spleen cells of some of these mice 
were tested for FV-induced cell membrane antigens by direct cytotoxicity. Of a 
total of 17 A.BY hybrid mice examined 30-105 days after FV, spleen cells of only 
2 (11.8%) were lysed by anti-FV serum and C', whereas all mice examined 8-11 
days after virus had speen cells which were lysed. These results could explain 
the observed coexistence of cytotoxic antibodies and leukemic splenomegaly. 
2  BALB  hybrids are much more susceptible to high FV doses than are A.BY hybrids (16),  and 
the doses used here were found optimal for expression of  the Rfv-1 genotype. 78  HUMORAL  IMMUNITY  AND  RECOVERY  FROM  LEUKEMIA 
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Fro.  2.  Comparison  of cytotoxic antileukemia cell  antibody  titers 30-35 days after i.v. 
inoculation of congenic F1 mice with FV. A.BY hybrids ([C57BL/10 × A.BY]F~ and [B10.A × 
A.BY]FI)  received  15,000 FFU  ([C57BL/10  ×  A.BY]Ft  FV  stock),  and  BALB  hybrids 
([C57BL/10  x  BALB.B]F~ and [C57BL/10  ×  BALB/c]F~) received 150 FFU (BALB.B  FV 
stock).  (e), splenomegaly; (O), normal spleen size. 
Role of Non-H-2 C57BL  Genes.  The  present  observations  of recovery from 
FV infection and the detection of neutralizing and cytotoxic antibodies in C57BL 
hybrid mice independent  of recovery from splenomegaly are in contrast to data 
obtained  with other mouse strains  (20)  where  neutralizing  antibodies  are only 
found  in  association  with  regression  of splenomegaly.  These  findings  suggest 
that  non-H-2  C57BL  genes  play  a  role  in  control  of FV  infection,  and  it  is 
possible that this control could be a  necessary prerequisite for ultimate recovery 
from  splenomegaly.  To  assess  whether  the  control  of  FV  infection  seen  in 
(C57BL/10  x  A.BY)F1  and  (B10.A  ×  A.BY)F1  mice was found  only  in  C57BL 
hybrid mice, we examined several C57BL hybrid mouse strains as well as their 
non-C57BL  parents  for presence  of viremia  30  days  after FV  inoculation.  The 
data,  shown in Table II, concern only mice with splenomegaly and indicate that 
in each group the C57BL  hybrid mice alone have a  high  incidence  of recovery 
from viremia in the presence of splenomegaly.  Mice lacking C57BL  genes only 
rarely recover from viremia in the presence of splenomegaly.  These results are 
not influenced  by genes of the H-2 complex. 
It  has  previously  been  noted  that H-2  (Rfv-1)  gene-mediated  regression  of 
splenomegaly can be clearly demonstrated only in C57BL hybrid mice (16).  One 
or more non-H-2 C57BL genes appears to be necessary for expression of this H-2- BRUCE  CHESEBRO  AND  KATHY  WEHRLY  79 
TABLE II 
Incidence of Viremia 30 Days after FV Inoculation  in 
Splenomegalic Mice 
Number  with  vi- 
Mouse strain  remia/total  with  Virus dose 
splenomegaly 
FFU 
BALB/c  2/2  300 
BALB.B  7/7  300 
(BALB/c x  A/J)F,  19/20  300 
(B10  ×  BALB)F~*  2/18  300 
A.BY  7/8  3,000 
(B10  x  A)F~$  4/43  3,000 or 30,000 
DBA/2  5/7  3,000 
(C57BL/6  ×  DBA/2)F~  0/11  3,000 
* Includes (C57BL/10 x  BALB.B)F~, (B10.A x  BALB.B)F1, (C57BL/10 × 
BALB/c)FI, and (B10.D2  x  BALB/c)F~. 
Includes (C57BL/10  ×  A.BY)Fh  (B10.A  ×  A.BY)F~,  and  (B10.A  x 
A/WySn)F~. 
associated effect. BALB.B mice (H-2 bib) were never observed to regress at doses 
studied,  while (C57BL/10  x  BALB.B)F1 mice (H-2 b/b) had  a  high incidence of 
regression.  3 Since the effect of C57BL genes is dominant in the F1, we studied 
the  incidence  of regression  of splenomegaly in  the  backcross,  (C57BL/10  × 
BALB.B)F1  ×  BALB.B. If a  single,  dominant,  non-H-2  C57BL gene were in- 
volved, one would expect near 50% incidence of regression; if two genes were 
involved, 25% regression; if three genes were involved, 12.5% regression, etc. 
Table III gives the results of studing 63 backcross mice. Only three regressors 
were found (4.8% incidence), which implies that three or more non-H-2 C57BL 
genes are necessary for expression of the H-2  (Rfv-1)-mediated  effect on regres- 
sion. Unfortunately these backcross mice were not examined for viremia, and so 
it is not possible to say whether the effect of C57BL genes on recovery from FV 
infection is also multigenic involving the same genes as the effect on regression 
of splenomegaly. 
Discussion 
The  present  work  has  attempted  to  clarify some  of the  roles  of humoral 
immunity in host defense against FV leukemia in mice. FV-induced antibody, 
together with complement, can lyse FV leukemia cells in vitro. As demonstrated 
in the present experiments, similar antisera can inhibit FV-induced neoplastic 
spleen foci even when administered as late as 3 days after virus inoculation. 
3 It  is theoretically possible that  a  maternal effect could  explain this difference since the 
mothers of the FI mice used were C57BL/10, not BALB.B. The reciprocal Ft cross will have to be 
tested to regorously exclude this possibility.  In the backcross experiment a  maternal effect is 
unlikely since the regressor F~  mice were the mothers of the backcross progeny, which in turn 
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TABLE  Ill 
Incidence of Regression of Splenomegaly  in Backcross Mice 
Number dead or with  Mouse strain 
splenomegaly/total 
BALB.B  22/22 
(C57BL/10  x  BALB.B)FI  3/27 
(C57BL/10  x  BALB.B)F~  x  BALB.B  60/63 
Mice were given B-tropic FV (30 FFU) i.v.; data presented are from 60 
days after virus inoculation in two separate experiments. 
Bearing in mind that humoral antibodies can kill neoplastic cells in vitro and 
inhibit formation of  neoplastic cell foci in vivo (21), we looked for evidence of  their 
effects in the spontaneous recovery from FV leukemia controlled by the Rfv-1 
gene.  Kinetic studies of FV growth and viremia in congenic mice differing at 
this gene suggest that neutralizing antibody plays a major role in control of FV 
infection. However, no such direct correlation between recovery from the leuke- 
mia and presence or titer of antibodies was demonstrated. Both progressor and 
regressor  C57BL  hybrid  mice  were  able  to  restrict  virus  proliferation  and 
develop high titers of neutralizing and cytotoxic antibodies. Antibody may be 
necessary for recovery to occur, but its presence alone is not sufficient to induce 
recovery. It should be noted that to get a countable number of spleen foci in the 
passive antibody transfer experiment the virus dose used was very low com- 
pared to the dose used in most recovery experiments. Initial virus dose has a 
profound effect on recovery incidence (15, 16), and it is possible that cytotoxic 
antibody may be  an  effective defense mechanism only against low  virus or 
leukemia cell burdens. 
The occurrence of neutralizing and cytotoxic antibodies in the face of concur- 
rent splenomegaly raises questions about the expression of virus-induced cell 
surface antigens on the leukemic spleen cells in the later stages of the disease. 
Presence of the antibodies in plasma implies that they are in excess over the 
amount of antigen exposed on cells in the spleen and other organs. The spleen 
cells  should be  coated with immunoglobulin if they possess  the  appropriate 
membrane antigens. Examination of these spleen cells with fluorescent anti- 
mouse Ig serum has provided no evidence that this is the case. 4 Furthermore, 
most late (>30 day) leukemic spleen cells used directly for targets in cytotoxicity 
tests with antibody and complement were negative for virus-induced antigens. 
Together these observations imply that tumor antigens on the leukemic spleen 
cells are decreased or altered at this time, and this may explain the persistence 
of leukemic splenomegaly in the face of high titers of cytotoxic antibody in these 
mice. The mechanism of this antigenic change is unknown. At the virus doses 
used many separate clones of neoplastic cells are transformed initially. Little is 
known about the pressures  of selection on these clones during the course  of 
disease. Antibody or other host defenses could selectively eliminate clones with 
a high antigen density leaving only those few clones with low antigen density to 
4  Chesebro, B., and K. Wehrly. 1975. Unpublished observations. BRUCE  CHESEBRO  AND  KATHY  WEHRLY  81 
proliferate. It is also possible that antibody itself  could play a role in inducing in 
vivo antigenic modulation (22). 
The loss of virus-induced cell membrane antigens seen late in FV leukemia 
has been noted previously to be influenced by the H-2 locus and could provide an 
explanation for the association of H-2 bib with recovery from FV-induced spleno- 
megaly in certain strains.  On the BALB genetic background, H-2 d~ mice lose 
cell membrane antigens and H-2 bib mice do not (23). Theoretically host immune 
defenses might more easily recognize and eliminate the neoplastic cells in the H- 
2 b~b mice. However, we have not seen a similar H-2 association of  this effect using 
C57BL hybrid mice. The 5-10% of Y10 (H-2 bib) mice which do not recover from 
splenomegaly do have decreased or altered virus-induced spleen cell membrane 
antigens similar to congenic H-2 a~b or H-2 a~ mice. It is possible that the progres- 
sor individuals which we are examining have not recovered because their spleen 
cells have decreased amounts of virus-induced antigen. Evidence against this 
possibility is the observation that recoveries do occur later than 30 days after FV 
inoculation, i.e., at a time when virus-induced cell surface antigen has already 
decreased. Thus it is unclear at this time whether or not the frequently observed 
reduction in  virus-induced cell  surface antigens has any relationship to the 
phenomenon of recovery from splenomegaly. 
It is clear that our results on viral growth kinetics, which were obtained in 
C57BL hybrid mice, are not identical to what has been observed in other mouse 
strains which lack C57BL genes (24). The Rfv-1 gene effect can be demonstrated 
dramatically  only  C57BL  hybrids  (16).  Experiments  using  (C57BL/10  × 
BALB.B)F1 x  BALB.B backcross mice showed that at least three other C57BL 
genes are involved in the expression of the Rfv-1  recovery phenomenon. Fv-2 
(25, 26) may be one of these genes. Data on control of viremia in various strains 
suggested a  similar effect of C57BL genes independent of Rfv-1,  although the 
number of genes involved was not determined. These results on recovery and 
viremia could be due to similar mechanisms possibly involving antibody. Mice 
that are  not C57BL hybrids are  able  to make FV  neutralizing antibody and 
cytotoxic antibody after appropriate immunization. Thus there is no absolute 
inability to synthesize these antibodies, but these mice could be more suscepti- 
ble to immunosuppression induced by FV than C57BL hybrids (27). Differences 
in interferon production could also be important in control of virus proliferation 
(28),  or  enhancement (29), or  suppression  (30, 31)  of the  immune  response. 
However, since both groups of mice can support virus replication to equal peak 
levels in the spleen, there doesn't appear to be any critical target cell deficiency 
or initial impediment to virus proliferation in C57BL hybrids. 
In summary, our data suggest that neutralizing anti-FV antibody may play a 
major role in elimination of viral infection, and that this may be a  necessary, 
but not alone sufficient, step in the process of recovery from FV-induced spleno- 
megaly. In several systems such antibodies have been shown by passive transfer 
to be effective in host defense against tumor cells (10, 32, 33). However, similar 
to  our  results,  in  the  Moloney sarcoma  virus  system  there  is  a  very  poor 
correlation of presence of these antibodies with tumor regression, and mice with 
progressing tumors have been found to have antibody titers in the same range as 
many regressors (34-37).  Antibody to virus-induced cell surface antigens can 82  HUMORAL  IMMUNITY  AND  RECOVERY  FROM  LEUKEMIA 
function in vivo against FV-transformed cells, but its occurrence in the presence 
of persistent splenomegaly suggests that it is not the major effector of the Rfv-1 
gene-controlled recovery phenomenon.  In  addition  the  observation of similar 
titers  of neutralizing  and  cytotoxic antibody titers  in  mice  of differing Rfv-1 
genotypes suggests that this gene does not act by controlling these aspects of the 
host  immune  response.  The  role of the  specific cellular  immune  response  in 
recovery will be examined in the following paper (38). 
Summary 
The  humoral  immune  response  to  Friend  virus  leukemia  was  studied  in 
congenic F1 mice differing in their incidence of recovery from leukemia.  Anti- 
viral neutralizing antibodies rose in titer in vivo concurrently with disappear- 
ance  of viremia  and  fall  in  spleen  virus  levels.  Cytotoxic antileukemia  cell 
antibodies also appeared at this time. Passive transfer of these antibodies could 
inactivate low numbers of leukemia cells in vivo; however, mice of both high 
and  low recovery genotypes produced antibodies  in equal  titer and recovered 
from viral infection in spite of striking differences in recovery from leukemic 
splenomegaly. Mice lacking C57BL genes did not produce antibodies or recover 
from viremia except in rare instances. Recovery from splenomegaly was found to 
be influenced by three or more C57BL genes independent of the H-2 complex. 
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